{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078142","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.393088+00:00","generated_at":"2026-05-17T13:27:23.975594+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Zura Bio Q2 2025 net loss $16.0M; cash $154.5M funds through 2027","bullets":["Cash and cash equivalents of $154.5M as of June 30, 2025, expected to fund operations through 2027.","Q2 2025 net loss of $16.0M ($0.17 per share) vs $10.3M ($0.17 per share) in Q2 2024.","R&D expenses rose to $8.7M (up $3.2M YoY) driven by Phase 2 studies for tibulizumab in SSc and HS.","Initiated TibuSHIELD Phase 2 for hidradenitis suppurativa; topline data expected Q3 2026.","Appointed Eric Hyllengren as CFO (July 2025) and Dan Becker, M.D., Ph.D. to Board (May 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078142","json":"https://secwatch.observer/filing/0001104659-25-078142.json","markdown":"https://secwatch.observer/filing/0001104659-25-078142.md","text":"https://secwatch.observer/filing/0001104659-25-078142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465925078142/0001104659-25-078142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465925078142/tm2522624d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:27:23.975594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}